EU nod for opioid dependence therapy
The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
Read More
Tag: Zubsolv
CHMP backs 13 treatments for EU approval
Thirteen new therapies – including two biosimilars – have been backed for approval in Europe.
Read More
MundiPharma, Orexo file Zubsolv in Europe
UK-based MundiPharma and Swedish group Orexo’s have filed opioid dependence drug Zubsolv in Europe.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
